SCHEMBL3785941

SCHEMBL3785941

C#CCCOS(=O)(=O)C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.54
CA9 Q16790 1/20 0.54
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3790388 0.88 CA2 (0.41) CA2CA9CA1
SCHEMBL3788536 0.86 CA2 (0.39) CA2CA9CA1
SCHEMBL23150453 0.84 CA2 (0.38) CA2CA9CA1
SCHEMBL14181931 0.78 CA2 (0.39) CA2CA9CA1
SCHEMBL1032931 0.78 CA2 (0.47) CA2CA9CA1
SCHEMBL17596857 0.78 TSHR (0.40) CA2CA9CA1
SCHEMBL577322 0.77 CA2 (0.35) CA2CA9CA1
SCHEMBL3789621 0.75 CA2 (0.37) CA2CA1
SCHEMBL20553030 0.75 CA1 (0.34) CA2CA1
SCHEMBL14052987 0.75 CA1 (0.34) CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-08-25 US disclosed
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-08-25 US disclosed
EP-3010345-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS The Regents of The University of California (US) 2016-04-27 EP disclosed
WO-2014205414-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-12-24 WO disclosed
WO-2014205414-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-12-24 WO disclosed
WO-2010118711-A2 NOVEL HELQUATS, THEIR PRECURSORS AND METHOD OF PREPARATION THEREOF Ústav organické chemie a biochemie Akademie ved Ceské republiky, v.v.i. (CZ) 2010-10-21 WO disclosed
US-5208244-A Administering substituted enol lactones WASHINGTON UNIVERSITY (US) 1993-05-04 US disclosed
US-5187174-A Biological antigrowth agents ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1993-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS NQO1, TXN2, MPO CA2 4271/4885CA9 4167/4885CA1 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.